newsfilter
← Latest News
ACCESS Newswire·

CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel

SOUTH SAN FRANCISCO, CA / ACCESS Newswire / February 25, 2026 / CASI Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38